Seoul – JW Pharmaceutical announced today, February 12, 2026, a company-wide campaign to raise awareness of anemia and the importance of early diagnosis and treatment. The initiative coincides with World Anemia Day, observed annually on February 13th, a date jointly established in 2022 by the Society for the Advancement of Blood Management (SABM) and the non-profit Human Touch Media Foundation.
The campaign involved distributing informational materials and content through JW Pharmaceutical’s internal communication channels, highlighting the significance of early detection and treatment for the condition. Employees also participated in a quiz focused on anemia, with prizes awarded to winners.
Anemia, characterized by insufficient oxygen delivery to the body’s tissues due to low hemoglobin levels, affects an estimated 2 billion people globally, according to the World Health Organization (WHO). The WHO defines anemia as a hemoglobin level below 13g/dL for adult men and 12g/dL for adult women.
Recent data from the Korean Disease Control and Prevention Agency indicates a 7.4% prevalence of anemia among the South Korean population aged 10 and older in 2024. The rate is significantly higher among women (12.7%) compared to men (2.5%). The condition is also more common in older adults, often linked to chronic diseases such as hypertension, diabetes, and inflammatory conditions.
Symptoms of anemia include fatigue, shortness of breath, weakness, and palpitations. If left untreated, anemia can lead to more severe complications, including cold extremities, headaches, dizziness, memory impairment, and an increased risk of acute myocardial infarction and cerebrovascular disease. A 2018 study published in the Journal of the American Heart Association found that individuals with hemoglobin levels outside the normal range over a two-year period had a higher risk of death from these cardiovascular events ten years later.
JW Pharmaceutical supplies “Ferinject” (feric carboxymaltose), a high-dose iron injection, and states its commitment to improving treatment options for patients with iron deficiency-related diseases. Ferinject allows for the replenishment of up to 1000mg of iron within a minimum of 15 minutes. The product is used for treating iron deficiency anemia in women at risk, patients with chronic bleeding, and those experiencing iron deficiency following surgeries or chemotherapy. Health insurance coverage for Ferinject was implemented in May 2024, and in May 2025, the approved uses were expanded to include children aged 1 to 13 years.
A JW Pharmaceutical representative stated the company will continue its efforts to raise awareness about anemia and “contribute to improving the treatment environment for patients with iron deficiency-related diseases,” adding that they will “continue to pursue various activities that can be of practical help to patients.”
